
Niki Karavitaki on the risk of brain tumours after radiotherapy for pituitary adenoma
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
Niki Karavitaki talks with The Lancet Diabetes & Endocrinology about the risk of a second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma.
Read the full article:
Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
What listeners say about Niki Karavitaki on the risk of brain tumours after radiotherapy for pituitary adenoma
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.